Please try another search
Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. It has a collaborative agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
Name | Age | Since | Title |
---|---|---|---|
Mogens Nielsen | - | 2020 | Director |
Bert Junno | 57 | 2014 | Non-Executive Director |
Olov Sterner | 70 | 2014 | Independent Director |
Katarina Gospic | - | 2021 | Director |
Anders Lonnberg | - | 2021 | Chairman of Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review